‘Unprecedented’ Survival Seen With Maintenance Tarlatamab for SCLC in Early Study

(MedPage Today) — The combination of tarlatamab (Imdelltra) and a PD-L1 inhibitor after first-line chemo-immunotherapy showed promise as a maintenance therapy in patients with extensive-stage small cell lung cancer (ES-SCLC), with a manageable…